Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Rocky9 who wrote (9655)	8/23/2006 1:04:18 AM
From: ritzkid8	Respond to of 10280

Anyone on the board care to speculate on the odds of a buyout at this point and what the immediate future of the company looks like if it doesn't happen? It's trading at pre-buyout rumor levels and I'm starting to question whether or not they even have viable suitors. On the flip side, if they can't or choose not to sell, what other options do they have? Lunesta sales have been flat for I don't know how long and the HFA launch was a joke. They continue to increase expenses and there is a major gap in the pipeline. I don't think the two deals they've done in the past (Ross Labs and Astelin) give investors much confidence in the management team to hit a home run with something new. I think the buyout premium in Sepracor is gone and the stock will continue to fall as investors start focusing on the company's lack of execution.